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Abstract 
Introduction: Neurodevelopmental disorders (NDDs) are common and severely debilitating. 
Their chronic nature and reliance on both genetic and environmental factors makes studying NDDs and 
their treatment a challenging task. Here, we discuss neurobiological mechanisms of NDDs, and present 
recommendations on their translational research and therapy, outlined by the International Stress and 
Behavior Society. 
Areas covered: Common NDDs are a heterogeneous group which includes autism spectrum 
disorder, intellectual disability, communication/speech disorders, motor/tic disorders and attention deficit 
hyperactivity disorder. Various drugs currently prescribed to treat NDDs also represent a highly diverse 
group. Acting on various neurotransmitter and physiological systems, these drugs often lack specificity 
of action, and are commonly used to treat multiple other psychiatric conditions. There has also been 
relatively little progress in the development of novel medications to treat NDDs. Based on clinical, 
preclinical and translational models of NDDs, our recommendations cover a wide range of 
methodological approaches and conceptual strategies. 
Expert opinion: To improve pharmacotherapy and drug discovery for NDDs, we need a stronger 
emphasis on targeting multiple endophenotypes, a better dissection of genetic/epigenetic factors or 
‘hidden heritability’, and a careful consideration of potential developmental/trophic roles of brain 
neurotransmitters. The validity of animal NDD models can be improved through discovery of novel 
(behavioral, physiological and neuroimaging) biomarkers, applying proper environmental enrichment, 
widening the spectrum of model organisms, targeting developmental trajectories of NDD-related 
behaviors and comorbid conditions beyond traditional NDDs. While these recommendations cannot be 
addressed all in once, our increased understanding of NDD pathobiology may trigger innovative cross-
disciplinary research expanding beyond traditional methods and concepts. 
 
Keywords: neurodevelopmental disorders, animal models, autism, ADHD, translational research 
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Article Highlights: 
 
 Neurodevelopmental disorders (NDDs) are common and widespread psychiatric illnesses caused by 
aberrant brain development 
 The chronic nature of NDDs and their strong reliance on both genetic and environmental factors 
complicates their treatment and prevention 
 Drugs currently used to treat these disorders lack specificity and are often ineffective 
 Here, we discuss neurobiology of NDDs and their available preclinical (experimental) animal 
models 
 Based on these analyses, we formulate recommendations to improve NDD drug discovery and 
pharmacotherapy 
 Improved understanding of NDD pathobiology is critical for fostering further innovative cross-
disciplinary research in the field of translational neuroscience and biological psychiatry 
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List of abbreviations: 
ADHD - Attention Deficit/Hyperactivity Disorder 
ASD - Autism Spectrum Disorder  
CAM – complementary alternative medicine 
CNS – central nervous system 
CD – Communication Disorder 
DSM – Diagnostic Statistical Manual  
FDA – Federal Drug Administration 
fMRI – functional magnetic resonance imaging 
GxE – gene-environment (interaction)  
G-E – gene-environment (correlation) 
GWAS - genome-wide association study 
ID - Intellectual Disability 
ncRNA- non-coding RNAs 
NDD – neurodevelopmental disorder 
PPI - pre-pulse inhibition 
PTSD – post-traumatic stress disorder 
RDOCs - Research Domain Criteria 
SERT – serotonin transporter 
SHR – spontaneously hypertensive rat 
SLD - Specific Learning Disorder 
SNP - single nucleotide polymorphism 
SSRI – selective serotonin reuptake inhibitor 
WGS – whole-genome sequencing 
WES - whole-exome sequencing 
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1. Introduction 
Neurodevelopmental disorders (NDDs) are caused by aberrant brain development resulting in 
cognitive, motor, language and affective deficits (Table 1)1. Common NDDs include autism spectrum 
disorder (ASD), social communication disorders, intellectual disability (ID), attention deficit 
hyperactivity disorder (ADHD), motor and tic disorders (Fig. 1a)1, 2. Aberrant neural development, 
usually beginning during early embryogenesis, causes a lasting dysregulation of a wide range of brain 
processes, including neurogenesis, glia/neuronal proliferation, cell migration, synapse formation and 
myelination (Fig. 1b)3-6. As genetic factors play a key role in NDDs (showing medium-to-high heritability 
estimates; Fig. 1b), they can also be evoked by environmental factors, such as maternal influences, 
nutrition or early exposure to immune challenges, toxicants, psychoactive drugs and stress. In addition 
to clinical studies, various animal models of experimental NDDs are widely used in translational research 
in this field (Tables 2-4).  
The growing socio-economic impact and high prevalence of NDDs require urgent attention to 
improving their therapy. The treatment and prevention of NDDs are complicated by their chronic nature 
and strong dependence on both genetic and environmental factors. With little progress in the development 
of novel medications for NDDs, the existing drugs often lack specificity of action, and are mainly used 
to treat other psychiatric conditions beyond NDDs7 (Table 3). Recognizing these important challenges, 
the International Stress and Behavior Society (ISBS) has established the Strategic Task Force on NDDs. 
Comprising international experts from different fields of biological psychiatry, the Panel 
comprehensively evaluated the neurobiological mechanisms, genetics, psychopharmacology and in-vivo 
animal models of NDDs. Based on mounting translational and preclinical evidence, the ISBS Task Force 
has made critical recommendations for improving pharmacotherapy of NDDs, which are summarized 
here. 
2. The complex genetics of neurodevelopmental disorders  
Described as a “ballet choreographed over time between the action of multiple genes, 
environmental and epigenetic factors”8, brain disorders often display complex, polygenic non-Mendelian 
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genetics9. Used to identify disease-causing variants, genome-wide association studies (GWAS) utilize 
multiple single nucleotide polymorphisms (SNPs) maintained in linkage disequilibrium10. However, the 
contribution of GWAS to our understanding of brain disorders, and NDDs in particular, has been limited 
so far9, partially due to the small sample sizes, the difficulty of ascertaining how SNPs alter gene function, 
the variability of clinical NDD symptoms and the poor operationalization of these symptoms into 
measurable entities. The common variants uncovered by GWAS only account for a small percentage of 
heritability estimates, with surprisingly poor correspondence of data across studies10, 11. Yet, in some 
cases, genome-wide approaches followed by fine-mapping may provide useful insights into the genetics 
of NDDs. For example, Latrophilin 3 (LPHN3) was identified as a human ADHD ‘susceptibility’ gene 
by linkage analysis of affected families12 and is now being confirmed in preclinical models of this 
disorder13.  
Increasing evidence indicates that some NDDs (e.g., ASD and ADHD) can also be triggered by 
mutations in single genes14-17. These genes often contain rare mutations with <1% of the minor allele 
frequency (the rate at which the less common allele occurs within a given population)10. Rare mutations 
include both SNPs and copy-number variants18 - deletions or duplications of chromosome segments of 
variable size that can affect single or multiple genes at the same time. Rare mutations can impact brain 
and its development in several ways. In addition to reducing gene function, disease-causing mutations 
may constitutively activate proteins, show dominant negative activity, or create new or abnormal 
biochemical functions19, 20. Furthermore, a single disease gene can be mutated in multiple positions, each 
of which may give rise to a very different phenotype. For example, a defect in a single gene, Disrupted 
in Schizophrenia 1 (DISC1), can lead to different disorders, including schizophrenia (psychoses), bipolar 
disorder, major depression or ASD, even when patients carry the same mutation21. Therefore, for NDDs 
with an unknown genetic basis, it may be critical to identify causative mutations in both known and novel 
genes.  
The non-Mendelian inheritance of some single disease-causing mutations can be explained by 
incomplete penetrance of the disease-causing alleles, by protective variants in the genetic background or 
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by the acquisition of novel mutations. Single mutations provide an excellent entry point for studying 
NDDs, as they are easier to model in animals, provide construct validity for the disease and offer 
opportunities to uncover the underlying neural circuits11. Furthermore, comparison of the effect of 
multiple mutations may also highlight the general changes in brain function that lead to pathogenesis22: 
just as “all roads lead to Rome”, alteration of the function of many genes may ultimately affect only a 
few common disease-causing pathways23 (see further). However, the relative contribution of rare or 
common mutations to disease susceptibility is currently unclear. Rather than being caused by a single 
type of genetic lesion, NDDs could be caused by a combination of many. For example, single mutations 
can predispose patients to ADHD, while other SNP polymorphisms in the genetic background (or 
mutations in a second critical gene) may alter the penetrance of the disease11. Thus, a single mutation 
may be necessary, but not sufficient, to trigger the disorder. Such a combined model may explain the 
large heterogeneity of NDD symptoms and their low penetrance often observed in patients and in 
preclinical models24.  
Since most of the rare mutations linked to NDDs affect genes active during embryonic 
development, even subtle changes can have far-reaching consequences for neural development and 
permanently alter the mature brain function25. In some cases, genetic mutations cause specific cellular 
phenotypes linked to neurological disorders, impairing symmetric cell division, differentiation, survival, 
neurite outgrowth, axon pathfinding and dendritic architecture26, 27. Alternatively, mutations may cause 
diffuse and variable changes to brain function by influencing the outcome of random variation at a 
number of developmental choice points, thereby affecting the global developmental trajectory of an 
organism28. Such broad phenotypic changes may cause miswiring of neural circuits, leading to altered 
brain function and pathophysiology29. Overall, diffuse changes to brain function seem likely when 
considering that genes do not directly control behavior, but rather act via the formation, connection and 
function of neural circuits in the brain. Thus, it is perhaps predictable that many disease-causing 
mutations are active during embryonic development, a time when embryos may be both more plastic and 
more susceptible to alteration.  
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3. Recommendations of the ISBS Strategic Task Force on neurodevelopmental disorders 
Outlined here are several strategies suggested by the ISBS Panel to foster translational research 
into the pathogenesis and treatment of NDDs (also see Table 5). Covering different aspects of 
translational cross-species and multi-phenotype modeling, these recommendations are expected to 
improve current and future drug discovery and pharmacotherapy of NDDs.  
4.1. Focus on multiple (vs. single) endophenotypes 
While prenatal neural development is associated with cell differentiation, neuronal outgrowth and 
network formation (Fig. 1b), after birth, these networks are refined by the experiences of the newborn 
that impinge on the ongoing developmental processes. Therefore, it is insufficient to elucidate 
neurodevelopmental mechanisms by studying individuals with full-blown disordered phenotypes. 
Indeed, it has been demonstrated that NDDs are associated with susceptibility genes that are relatively 
upregulated in the prefrontal cortex during fetal life30. For example, genes associated with syndromic 
NDDs (e.g., ID and ASD), are relatively enriched in prenatal transcript abundance compared with the 
overall transcriptome, whereas genes associated with neurodegenerative disorders are significantly 
under-expressed during fetal life30. In addition, during normal prefrontal cortex development, gene 
splicing changes are most frequent early in development. More than 60% of all splicing changes 
represented a single splicing pattern reflecting preferential inclusion of gene segments potentially 
targeting transcripts for nonsense‐mediated decay in infants31. Risk for NDDs is increased when 
nonsense-mediated mRNA decay becomes aberrant32. Thus, it is essential to follow developmental 
processes before phenotypes become overt. Some of these processes may remain sub-threshold and not 
present recognizable features. Even in this case, a feature appearing will not lead to a diagnosis. As a 
consequence, a continuum in developmental processes and associated phenotypes is expected. 
Longitudinal and prospective cohort studies providing information about maternal and paternal genotype 
and personality, prenatal factors, and genotype, brain morphology and function, life events and 
developmental milestones can provide important insights into this continuum of developmental processes 
and phenotypes that predispose to the full-blown diagnosed disorder. However, such studies require a 
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large number of subjects and more budget, given clinical heterogeneity of NDDs (Fig. 1a-c). 
Traditionally, experimental modeling of NDDs and other brain disorders is performed by mimicking their 
behavioral (affective, cognitive, social, motor or reward) endophenotypes8, 33. Current preclinical studies 
of NDDs may therefore benefit from modeling the dynamic interplay of multiple pathogenic 
endophenotypes (and their sensitivity to pharmacotherapy) rather than focusing on individual phenotypes 
or their screens. Note, however, that this approach can be complicated in longitudinal studies (revealing 
phenotypes and mechanisms occurring before the onset of the full-blown disorder). Thus, development 
of novel ‘early’ biomarkers or endophenotypes of NDDs, and performing both short-term and ‘clinic-
like’ longitudinal experiments in animal models, is recommended. 
4.2. Dissect genetic and epigenetic influences 
Modern genetic sequencing tools have revealed multiple previously unknown genes linked to 
NDDs. Many of the sequencing studies performed to date have utilized whole-exome sequencing (WES), 
which focuses only on the ~2% of the human genome that encodes proteins. Recently, the Encyclopedia 
of DNA Elements (ENCODE) project found that the non-coding regions of the genome not sequenced in 
typical WES play crucial regulatory functions in cellular dynamics and pathways75. In contrast, whole-
genome sequencing (WGS) attempts to scan the majority of the genome for disease-linked genetic 
variants, and is successful in small cohorts of ASD patients57,76. While WGS poses financial challenges, 
this Panel recommends an increased focus on WGS, as this may lead to further discoveries of rare variants 
in non-coding RNAs (ncRNA) and other regulatory regions contributing to NDDs. The examination of 
non-coding genomic regions and ncRNA also highlights the need for detailed epigenetic analyses of 
NDDs. Indeed, epigenetics play a critical role in the pathogenesis of Angelman syndrome (loss of 
imprinting at UBE3A), Fragile X syndrome (hypermethylation of FMR1 promoter caused by trinucleotide 
expansion), and Rett syndrome (mutation in the epigenetic enzyme MECP2)77,78. Mutations in genes 
coding for chromatin-modifying enzymes were also recently identified in ASD60. Therefore, we call for 
the detailed investigation of both epigenetic markers (e.g., histone acetylation/methylation and DNA 
methylation) in NDDs, as well as deep sequencing analysis of genes encoding epigenetic enzymes (such 
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as MeCP2, DNA methyltransferases and histone deacetylases/acetyltransferases), since mutations in 
these enzymes may play a role in stochastic epigenetic variation and transgenerational epigenetic effects 
(e.g., 79).  
4.3. Focus on symptoms that bridge across several neurodevelopmental disorders 
The symptoms of NDDs frequently overlap (Fig. 1b), providing an opportunity to uncover 
common down-stream pathways that affect multiple diseases. For example, aggression is a common 
comorbid symptom of ASD, ADHD, schizophrenia, conduct disorder and some types of depression34. 
Although heightened aggression levels can prevent treatment of other symptoms of a disease, the neural 
circuits that control this behavior are not well understood. Additionally, there are currently few 
medications that specifically target this behavior and, therefore, an urgent need for effective 
pharmacotherapy. Therefore, studying the genetic and neurological basis of behaviors that are present 
across neurodevelopmental disorders may provide insight into each separate disease. This 
recommendation is generally consistent with the recently proposed Research Domain Criteria (RDOCs) 
of the US National Institutes of Health (NIH) to address mechanisms and phenotypic dimensions, rather 
than symptomatic categories, of psychiatric diagnoses80. By focusing on discrete phenotypes, rather than 
on whole, criteria-based NDDs, new insights may be gained that would have otherwise remained 
obscured. 
4.4. Address the problem of ‘hidden heritability’ 
The problem of ‘hidden’ (missing) heritability35 is highly relevant to pathobiology of NDDs, since 
impaired neural development often causes global behavioral and cognitive deficits. This, in turn, may 
mask disorder-specific phenotypes, which may then become undetectable by conventional (e.g., GWAS) 
analyses. Recognizing its potential importance, we call for more thorough analyses of ‘hidden 
heritability’ of NDDs in both clinical and preclinical studies. Additionally, given the importance of 
epigenetic factors in CNS modulation, detailed analyses of epigenetic variation81 (both inherited and 
random) may further contribute to the "missing heritability" of complex brain disorders, such as NDDs. 
For example, genetic risk for a specific NDD may be passed through the germline by either “true” 
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epigenetic inheritance (i.e., an epigenetic mark that is present in the germline and inherited across 
multiple generations) or by mutations in epigenetic enzymes which may bias the chromatin confirmation 
of a patient36, 37, thus increasing the risk for diagnosis of a particular NDD. 
4.5. Examine potential developmental role of neuromediators 
Serotonergic drugs, such as SSRIs, are commonly used to treat NDD symptoms (Table 3). 
Mounting evidence suggests that some neurotransmitters, such as serotonin, may play a dual role in the 
brain, acting as both classical neurotransmitters and developmental ‘neurotrophic’ hormones38. For 
example, although the genetic ablation (knockout) of serotonin transporter (SERT) in mice shares some 
similarities with the effects of postnatal SSRI exposure, some differences exist, including anxiety and 
elevated extracellular serotonin levels in SERT knockouts vs. reduced serotonin levels and anxiety in 
adult mice following early postnatal SSRI (escitalopram)39. Therefore, it remains unclear to what extent 
serotonin-mediated neurodevelopmental changes contribute to serotonin-related traits, and whether such 
traits are solely dependent on serotonin levels per se. The developmental phase during which serotonergic 
perturbations take place can play a crucial role, as during the late prenatal phase in rodents  serotonergic 
neurons grow and migrate, whereas at the early postnatal phase brain circuits are shaped and refined40. 
Furthermore, it remains unclear whether and which serotonin-mediated structural neurodevelopmental 
changes contribute to behavioral phenotypes of NDDs. Therefore, approaches like in-utero 
electroporation and manipulating Sert expression during embryonic development may help clarify the 
postnatal structural and functional neurodevelopmental role of serotonin. Focusing on developmental 
processes during the postnatal period, the use of conditional knockout animals may further reveal how 
changes in neural development contribute to NDD-like behavioral phenotypes. For example, SSRIs used 
during pregnancy cause subsequent developmental delays, increased social behavioral disturbances and 
increased risk for ASD41, 42 in children. In addition, SSRIs induce chromatin alterations, suppressing 
protein kinase calmodulin-dependent protein kinase II (CaMKII) transcription in the rat nucleus 
accumbens36. Collectively, this suggests a larger (than traditionally recognized) role for central serotonin, 
as it can modulate NDDs directly as neurotransmitter, and indirectly as a neurotrophic developmental 
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hormone. Investigating this emerging complexity, and its implications for pharmacotherapy of NDDs, 
are recognized by this Panel as an important strategic direction of research. 
4.6. Improve the validity of animal models and biomarkers 
Given their immense translational importance, we recommend the continued use of genetically-
modified animal models to investigate the neurobiology of NDDs, with a particular focus on genes 
involved in synaptic function and epigenetic modification2,60. However, efforts should also focus on the 
development of environmental epigenetic models that recapitulate early life factors and may be involved 
in these disorders. The combination of these preclinical models will be crucial in identifying gene x 
environment interactions important for the progression of NDDs. Notably, basic research continues to 
over-utilize male animals and cells43. As various NDDs demonstrate robust sex differences (Fig. 1), 
both sexes must be included in a balanced manner in preclinical studies to improve drug discovery. 
Likewise, with the growing availability of rodent or fish strains for NDD research, a few selected inbred 
strains are typically used for drug screening assays, to ensure a better genetic control of the experiments44. 
As the global human population is highly heterogeneous genetically, a more balanced use of both inbred 
and outbred animal strains in CNS drug discovery may lead to more valid treatment and side-effects data, 
reflecting ‘demographic’ aspects of drug action and providing important clinical insights. Finally, 
although biological markers are not yet approved as part of the diagnostic criteria for NDDs, they may 
help predict the potential disease trajectory, and support decisions for specific early therapeutic and 
prophylactic measures. Other well-validated physiological biomarkers relevant to NDDs include fMRI 
imaging and, more broadly, other electrophysiological markers (e.g., mismatch negativity) which have 
shown high sensitivity to NDDs80, 81. We strongly emphasize the need to validate and discover new 
predictive markers of neurodevelopmental markers, in order to improve both drug discovery and 
pharmacotherapy. 
4.7. Widen the spectrum of model organisms 
Preclinical animal models are a critical tool in biological psychiatry45, including translational 
modeling of NDD-related phenotypes and pathogenesis. For example, rodent models of social 
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interaction, communication deficits and repetitive behaviors are relevant to studying ASD, whereas 
rodent hyperactivity and/or inattention can parallel clinical ADHD. Although rodents are currently the 
most commonly used animal model in the pre-clinical research (Fig. 2), they are limited by lower 
throughput and costs45. Therefore, increasing the spectrum of model organisms is recognized as an 
important strategy in biological psychiatry, and is fully endorsed by the ISBS. This endorsement is even 
more based on the conceptual value of identifying core, evolutionarily conserved pathogenic mechanisms 
of brain disorders – which can only be achieved by modeling brain disorders across taxa57, 59. For 
example, zebrafish (Danio rerio) are a time-efficient and low-cost model with high genetic and 
physiological homology to humans (Fig. 2)46, 47. They also show rapid development, which beneficial for 
NDD models larval zebrafish display robust motor and affective behaviors48 (which can be then 
monitored throughout the 4-year lifespan). In adult zebrafish, group behavior (shoaling) can be a useful 
model of ASD49, whereas hyperlocomotion, impulsive swimming and inattention in both larval and adult 
zebrafish can be relevant to ADHD50, 51. Chicks (Gallus gallus) also display robust social and locomotor 
phenotypes, recapitulating several NDD symptoms, including social deficits, accompanied by aberrant 
brain growth52 and affective behaviors53, 54. Likewise, non-human primates, such as common marmosets 
(Callithrix jacchus), represent another useful model organism with robust social and affective 
behaviors55, 56 highly sensitive to environmental manipulations that cause NDD-like phenotypes (e.g., 
ASD-like social deficits or ADHD-like pathological  hyperactivity56). Finally, complementing vertebrate 
models, invertebrate models (e.g., fruit flies, Drosophila melanogaster) are also demonstrating potential 
for modeling some aspects of NDDs57-59. Although these models have been comprehensively evaluated 
in the literature (see above), and will not be discussed here in detail, increasing the spectrum of model 
organisms is recognized by this Panel as one of the top priorities in translational NDD research. 
4.8. Assess the role of environmental enrichment 
There is currently a growing interest in the impact of early life adversity on neural development. 
Less attention, however, has been paid to the effects of environmental enrichment. Rearing laboratory 
animals in a complex, enriched environment can stimulate the development of the CNS, aid in 
15 
 
recovery of brain function following acquired injury, and improve performance on many cognitive 
and behavioral tasks, affording it special interest in the study of NDDs37, 60, 61. The potential for 
modulation of NDD phenotypes by enriched environments has received some attention (e.g., in 
particular, with respect to refinement of animal models), and evidence is emerging that the effects of 
some teratogen-linked NDDs can be improved by environmental enrichment62. For example, 
environmental enrichment reverses pre-pulse inhibition (PPI) deficits, alterations in pain sensitivity, 
stereotypic behavior, and social behavioral deficits in a mouse model of ASD induced by pre-natal 
valproate exposure62. Furthermore, environmental enrichment can significantly improve both the 
physical and behavioral response to prenatal alcohol exposure in rodents63-65 and enhance cognitive 
performance in spontaneously hyperactive rats (SHR), a genetic model of ADHD66. Although the 
mechanisms of action on NDD-related phenotypes are not particularly well understood, they may 
include the modulating effects of environmental enrichment on brain neuroplasticity and the efficacy 
of dopamine receptors in the pre-frontal cortex67, 68. Therefore, gaining a more thorough understanding 
of the role of environmental enrichment on the modulation and mediation of NDDs will be of critical 
importance moving forward. Additionally, the Panel emphasizes the interaction of genetic factors and 
environmental enrichment on the affectation of NDDs as a potential priority for further research in 
this field. 
4.9. Address Gene-Environment interactions vs. Gene-Environment correlations 
The Gene x Environment interactions (GxE) characterize how genotypes modify the sensitivity 
to environmental factors, and are widely analyzed in neuropsychiatric research. The gene-environment 
(G-E) correlations represent another important source of variation for complex behavioral traits, 
reflecting the individuals’ exposure to the environment as a function of their genotype69. The 
understanding that environment is not a static uniform factor, but can partly depend on individual’s 
own behavior, is an important conceptual development in modern biological psychiatry69. This 
concept has direct implications for NDDs and their association with environmental factors, especially 
those which are behaviorally modifiable (e.g., social environment). Consider, for example, parent-
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offspring and early peer-peer interactions, which represent ‘early’ reciprocal social interactions during 
neural development69. While most animal studies view the ‘environment’ as a static factor equally 
imposed on all animals in the laboratory, our ‘real life’ experience depends on subjects’ behavior with 
parent, relatives or peers. For children with genetically caused poorer social skills (e.g., ASD), their 
peculiar mode of interactions with others can make social environment more adverse, compared to 
‘smoother’ healthy subjects. On the one hand, such behaviorally-mediated interactions with the 
environment may affect neural development in a correlated (or even synergistic) manner. On the other 
hand, breaking this vicious pathogenetic cycle may reduce the negative impact of environmental 
adversity, therefore contributing to a better therapeutic outcome. The Panel recognizes the growing 
importance of G-E correlations in NDDs, and recommends more animal and clinical studies of 
reciprocal influences between environment and neural development.    
4.10.  Use imaging phenotypes in the field of neurodevelopmental disorders 
Modern imaging technologies enable in vivo monitoring of NDDs and in vivo assessment of the 
efficacy of novel pharmacological treatments. Magnetic resonance imaging and diffusion weighted 
imaging are established longitudinal methodologies for identifying neuroanatomical alterations. Three-
dimensional brain atlases exist for a range of species and enable automatic segmentation of brain regions 
to identify differences in volume or white matter microstructure70-75. These imaging modalities have been 
widely used to study various NDDs, including ASD, ADHD and ID76. More recent functional imaging 
techniques have begun to identify the neural circuitry linked to the behavioral and social phenotypes 
relevant to NDDs. For example, manganese-enhanced magnetic resonance imaging77-79 and functional 
magnetic resonance imaging (fMRI)80, 81 can identify abnormal circuitry, while optogenetics permits 
identification and precise manipulation of the circuitry related to neurological disorders82-84. In vivo 
imaging also plays an important role in drug discovery – e.g., as it helps to establish vital biomarkers that 
are necessary to determine if therapeutic candidates have elicited their targeted biological effects85. 
Following identification of a disease biomarker, imaging can then be used to profile drug mechanisms, 
efficacy, and safety. A wide range of such techniques include ultrasound, magnetic resonance 
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spectroscopy, positron emission tomography, single-photon emission computed tomography, and optical 
imaging methods (e.g., near-infrared fluorescence microscopy)86. Method to generate transparent brains 
are now also emerging87, which jointly with novel microscopic techniques enable 3D brain imaging. Each 
technique has different spatial resolutions and time scales, resulting in unique advantages and limitations. 
As a result, studies should carefully consider which technique(s) are best suited to produce desired 
conclusions. Overall, the Panel recognizes the value of the diversity of neuroimaging tools, as well as 
simultaneously analyzing physiological biomarkers and genomic/epigenetic mechanisms. We strongly 
believe that increased understanding of NDDs must be paralleled by advances in imaging. Imaging can 
play a large role in many suggestions of the Panel listed here, such as identifying similarities and 
differences between sexes or strains, developing canonical template spaces for new animal models, 
investigating the effects of environmental enrichment, and longitudinal investigations of brain 
development. Ultimately, by combining with existing behavioral and social paradigms, imaging 
methodologies will further foster translational research of NDDs. 
4.11. Increase focus on neurodevelopmental trajectories  
Many NDDs are triggered during embryonic development and their symptoms predominantly 
affect children or young adults. However, the majority of studies in animal models have focused on the 
behavior and neurobiology of fully mature adults. We recommend that research be extended to more 
actively include juvenile animals as well. The adolescent brain undergoes widespread developmental 
changes that affect axon guidance and proliferation, circuit wiring, and synaptogenesis and pruning. 
These structural changes are associated with the modulation of genetic and epigenetic factors. As NDDs 
likely affect these processes, a critical step will be to compare neuronal position, connectivity and the 
function of neural circuits in brains that are not yet fully mature, as well as their underlying molecular 
mechanisms. For example, ADHD has been linked to a delay in brain maturation and aberrant 
myelination, manifested as a reduced volume and aberrant microstructure of the white matter88, 89. 
Furthermore, the effect of pharmacotherapy on brain development trajectories should also be investigated 
further (Fig. 3).  
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4.12. Widen the spectrum of disorders relevant to NDDs 
NDDs frequently overlap with other neuropsychiatric disorders, including anxiety, depression, 
schizophrenia and post-traumatic stress disorder (PTSD, Fig. 1). Therefore, expanding the spectrum of 
NDD-related disorders is an important strategy in translational NDD research, and can include modeling 
brain illnesses that are not conventional NDDs. Consider, for example, the potential link between NDDs 
and PTSD, as neurodevelopmental deficits can later make an adult individual more vulnerable to stress, 
thereby triggering or exacerbating developing PTSD after a traumatic event 90, 91. Alternatively, 
depending on age, early traumas (e.g., child abuse) could potentiate neurodevelopmental deficits, which 
will parallel the developing PTSD symptoms. Thus, vigilant pharmacotherapy of PTSD may represent 
an important adjunct therapy to prevent or reduce NDDs (Fig. 1). The finding that some NDD symptoms 
(Table 3) and some forms of PTSD exhibit improvement following treatment with SSRIs suggests a role 
of the serotonergic system in these mechanisms92. Two SSRIs, paroxetine and sertraline, are currently 
the only FDA-approved pharmacological treatments for PTSD. However, response rates to SSRIs in 
PTSD patients rarely exceed 60%, whereas full remission following SSRI treatment is achieved in only 
20-30% cases93. An indication of the accentuated sympathetic activity in PTSD patients is the 
hyperresponsivity to the administration of yohimbine, an α2-adrenergic receptor antagonist that inhibits 
noradrenergic autoreceptors and increases central norepinephrine activity94. Along with a generally 
greater baseline norepinephrine levels in PTSD patients, this indicates a critical role of this 
neurotransmitter in the hyperarousal component of PTSD. Based on observed hyperactivity of the 
noradrenergic system in PTSD, the efficacy of anti-noradrenergic drugs in treating the disorder is 
supported by the use of propranolol, a β-adrenergic receptor antagonist, to reduce PTSD symptoms when 
administered after a traumatic event or with re-experiencing a traumatic memory95. Moreover, in 
preclinical studies, stress consistently increases glutamate levels, inhibits glutamate uptake, increases the 
expression and binding of glutamate receptors and increases calcium currents. For example, the primary 
effect of tianeptine involves the stabilization of glutamatergic neurotransmission and the enhancement of 
synaptic plasticity, particularly under stress conditions96 – the two mechanisms that may bridge NDD- 
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and PTSD-related pathogenesis. Taken together, this evidence suggests that examining disorders not 
normally considered as NDDs, such as PTSD, may provide new important insights leading to novel 
treatments that may be beneficial for comorbidity with, and/or target some symptoms of, NDDs. 
5. Conclusion 
In recent years, research into NDDs has revealed important information about their pathogenesis 
and underlying biology. However, due to the challenging and complex nature of NDDs and their shared 
or unique etiologies, many of the neural mechanisms involved remain unknown, resulting in a lack of 
effective treatment options for patients. Increasing the throughput of the translational pipeline from in-
vitro assays to clinical trials (Fig. 3), and using mechanistic insights generated from experimental 
observations, will lead to novel effective, target-specific therapies available to patients suffering from 
NDDs. 
5. Expert Opinion 
Translational in-vivo research aims to replace symptomatic drug therapies with those based on a 
principled understanding of the disease causes. In relation to NDDs, this process can be presented as a 
translational cycle with four multidisciplinary steps (Fig 2). The first step, animal modeling, uses animals 
to examine cognitive, motor and social behaviors, and their underlying genetics, molecular biology, 
neurophysiology and anatomy. Next, therapeutic strategies step aim to design interventions based on 
biological findings in animal models and optimize drug safety and efficacy. The drug development step 
then involves optimization of lead compounds to improve drug-target specificity, bioavailability and 
pharmacokinetics, as well as to determine the most efficacious dose, dosing strategy and route of 
administration. Finally, clinical trials examine the drug’s therapeutic effects as well as their behavioral 
and cognitive effects in humans (Fig. 2 and 3).  
Careful study of brain pathology and behavior establishes how well an animal model represents 
human disease (Step 1). Therapeutic strategies are evaluated in animal models by measuring deficits in 
performance in various behavioral tasks (Step 2, Table 2). A particular therapeutic strategy may address 
only a subset of cognitive or motor functions, so multi-target therapies that correct distinct deficits and 
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brain areas may be desirable. Drug development optimizes a therapeutic compound to improve drug-
target specificity, reduce or eliminate dangerous side effects, and determine dose and route of 
administration (Step 3). Finally, a lead compound enters clinical trials to test the safety and efficacy of 
therapeutic strategies discovered in animal models (Step 4). An approved pharmacotherapy for a NDD 
(see Table 3 for a partial listing of currently used and approved drugs) would reduce one or more 
cognitive deficits or maladaptive behaviors. Such a therapy completes the translational cycle by 
addressing the disease phenotype. However, animal models are often an imperfect representation of 
human disease or developmental disorders, and the differences between species may carry special 
significance for disease pathology97-99. Thus, improved characterization of animal models of NDDs 
requires better behavioral assays and physiological measurements. In addition, a better dissection of 
genetic determinants of NDDs is necessary - especially since, as already mentioned, even a single 
mutation can result in different CNS diseases within family pedigrees100. 
New animal models developed in the future will hopefully improve the correspondence with 
human conditions we hope to achieve, especially since more specific and efficacious second-generation 
therapies will require improved descriptions of the mechanisms underlying successful 
pharmacotherapeutic intervention. Once new and effective therapies are developed for NDDs by 
preclinical studies, designing and executing their clinical trials will require coordinated effort and 
significant resources from academia, government, private foundations and pharmaceutical companies.  
Discussing the neurobiological mechanisms of NDDs, the Special Task Force of the International 
Stress and Behavior Society (ISBS) has presented recommendations on improving drug discovery, 
pharmacotherapy and translational research of NDDs. Based on clinical, preclinical and translational 
models, these recommendations cover multiple areas ranging from methodological considerations to 
conceptual strategies of future research (Fig. 3). We realize that these recommendations cannot be 
addressed all in once, and that studies employing experimental animals will always remain an 
approximation of the human condition. Despite these limitations, increasing our awareness of factors 
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relevant for improved understanding of NDDs will advance this field and may trigger innovative cross-
disciplinary research that goes beyond traditional methods and concepts.  
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Figure 1. Neurodevelopmental disorders (NDDs) and their treatment. Panel A outlines therapeutic 
approaches to treating NDDs and associated other neuropsychiatric illnesses (see Table 1). ASD – autism 
spectrum disorder, ADHD – attention deficit hyperactivity disorder, OCD – obsessive compulsive 
disorder, PTSD – post-traumatic stress disorder. Panel B shows the ontogenetic timeline of key neuronal 
processes related to neural development, as well as the prevalence and heritability estimates (bottom left) 
and key behavioral symptoms (bottom right) of NDDs; ID – intellectual disabilities, CD – communication 
disorders. Panel C shows high comorbidity rates among NDDs and with selected other related disorders 
(ICD – impulse control disorder).  
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Figure 2. Steps involved in in-vivo development of anti-NDD therapies. Animal size reflects the 
relative usage of respective species (rodents, chicks, hon-human primates, zebrafish, fruit flies) in NDD 
research 
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Figure 3. The proposed integrative approach to improving pharmacotherapies of clinical 
neurodevelopmental disorders (NDDs), based on the recommendations proposed by the ISBS Task 
Force on NDDs 
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Table 1. Major groups of neurodevelopmental disorders currently listed in Diagnostic Statistical 
Manual (DSM-5)1 
 
Disorders  Major symptoms Availability of 
animal models 
Intellectual Disabilities (ID): Impaired mental functions in conceptual (language, reading, writing, 
knowledge, interpretation), social (empathy, compassion, judgment, 
communication, harmony) and practical (personal care, financial 
management, hobby) aspects 
+ 
Communication Disorders  Difficulties in language, speech, phonetic fluency or social 
communication 
?* 
Autism Spectrum Disorder 
(ASD): 
Persistent deficits in reciprocal social communication and 
interaction, as well as restricted, repetitive patterns of behavior, 
interests or thoughts 
+ 
Attention-Deficit/Hyperactivity 
Disorder (ADHD): 
Impaired attention with bursts of hyperactivity/impulsivity + 
 
Specific Learning Disorder: Difficulties with learning skills like reading, writing or spelling Not possible 
Motor Disorders Impaired execution of coordinated motor skills, or repetitive motor 
behaviors 
+ 
Tic Disorders Habitual sudden, rapid, recurrent and non-rhythmic motor 
movements or vocalizations (including Tourette’s syndrome) 
+ 
 
* While animals do not have language, their vocalizations (e.g., rodent USVs, bird songs or primate ‘calls’) may potentially 
be relevant to modeling neurobiological bases of communication  
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Table 2. Selected animal (rodent) models of neurodevelopmental disorders. ID – intellectual 
disabilities, ASD – Autism Spectrum Disorder, ADHD – Attention Deficit/Hyperactivity Disorder, SLD 
– Specific Learning Disorder, CD – communication disorders (see Table 1 for details). 
 
Rodent models Availability in other model organisms Clinical relevance 
Zebrafish Chicks Primates  
Social/preference tests + + + Social deficit in ASD 
Social recognition + + + Social deficit in ASD, ID 
Open field test + + + Hyperactivity in ADHD 
Various memory tests + + + Cognitive deficits in ID, SLD and ADHD 
Various attention tests + + + Attention deficits in ADHD 
Various impulsivity tests + + + Increased impulsivity in ADHD 
Self-grooming test    Behavioral perseverations in ASD and tics 
Aggression test + + + Aggression in ID, ADHD 
Marble burying test    Behavioral perseverations in ASD 
Ultrasonic vocalizations  + + Social deficits in ASD, ID or CD 
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Table 3. Main drugs currently used to treat major neurodevelopmental disorders (NDDs). ASD – 
autism spectrum disorder, ADHD – attention deficit hyperactivity disorder  
Drugs Main profile and mechanism of action NDDs treated 
Risperidone (Risperdal) Atypical antipsychotic, blocks D2 and 5-HT2A receptors  Tics, ASD*,** 
Haloperidol (Haldol) Typical antipsychotic (neuroleptic), blocks D2 receptors Tics* 
Pimozide (Orap) Typical antipsychotic (neuroleptic), blocks D2,D3 and D4 receptors Tics* 
Clonidine (Catapres) Sympatolytic α2 adrenergic- and imidazoline receptor agonist Tics, ADHD* 
Aripiprazole (Abilify) Atypical antipsychotic, partial agonist at dopamine and 5-HT receptors Tics, ASD*,** 
Atomoxetine (Strattera)  Non-stimulant norepinephrine reuptake inhibitor ADHD* 
Methylphenidat (Ritalin) Stimulant, dopamine-norepinephrine reuptake inhibitor ADHD* 
Lisdexamfetamine (Vyvanse) Stimulant prodrug, blocks monoamine uptake ADHD* 
 Olanzapine (Zyprexa)  Binds to α1, dopamine, histamine H-1, muscarinic, and 5-HT2 receptors ASD 
 Ziprasidone (Geodon) Blocks dopamine/serotonin receptors and monoamine reuptake ASD 
 Adderall*** Stimulant amphetamines, block dopamine-norepinephrine reuptake ADHD* 
Buspirone (Buspar) Anxiolytic, serotonin 5-HT1A receptor partial agonist ADHD, ASD 
Naltrexone Antagonist of μ-opioid receptor  ASD 
SSRIs**** Antidepressants, selective serotonin reuptake inhibitors ASD, ADHD 
 
* US Federal Drug Administration (FDA)-approved drugs 
** Mostly used to treat aggression associated with ASD 
*** A combination of amphetamine and dextroamphetamine 
**** Mostly used to treat some (e.g., aggression, affective deficits) aspects of NDDs, but can trigger neurodevelopmental 
deficits in off-spring 
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Table 4.   Examples of various tests to characterize neural development and behavior of young 
and adult rodents.  
Category Tests 
Simple reflexes  
 
Sensorimotor (pupillary, salivation, lacrimation) reflexes, acoustic startle*, limb grasping, 
somatomotor (loss of crossed-extensor reflex and rooting response, vibrissae response) 
Sensory and 
motor 
Cliff avoidance*, olfactory discrimination*, righting, gait analysis, rotarod, grip strength test, 
nest building, rope climbing test, vertical screen, self-grooming analyses and the open field test* 
Attention Various attention tests* 
Cognitive Olfactory conditioning*, T-maze*, Morris water maze, passive and active avoidance tests*, 
operant conditioning schedules*, homing and object recognition tests* 
Social Ultrasonic vocalization, social interaction* and social preference tests* 
Emotionality Elevated plus maze, light-dark box*, social interaction test*, self-grooming analysis 
 
* Conceptually similar tests are also available for aquatic (zebrafish) models, illustrating evolutionarily 
conserved trains across species 
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Table 5. Summary of selected additional strategies to improve drug development to treat 
neurodevelopmental pathogenesis 
Strategy Comments 
Innovate drug selection and screening  Use a wider spectrum of compounds, especially those beyond 
traditional mechanisms of anti-NDD therapy 
Develop disorder-specific drugs Drugs targeting ASD vs ADHD or depression 
Develop sex- and age-specific drugs For different disorder subtypes and cohorts 
Parallel behavioral changes with 
electrophysiological biomarkers 
Use neuroimaging approaches (e.g., functional magnetic resonance 
imaging or mismatch negativity analyses) sensitive to NDDs* 
Focus on additional disorders and their 
comorbidity 
E.g., with PTSD, aggression, anxiety and psychoses 
Focus on ‘adult’ developmental disorders beyond 
DSM-5 
E.g., child and adult PTSD and depression 
Uncover what NDD phenotypes are shaped by 
neurodevelopmental vs. neurochemical changes  
Use of conditional transgenic animals and/or prenatal 
environmental factors 
Establish developmental timelines of phenotypes 
preceding the full-blown onset of NDDs 
Apply longitudinal studies 
Examine gene-environment correlations Refine analysis of mother- and father-offspring, as well as early 
‘peer-peer’ social interactions 
Assess developmental genomic responses in CNS 
in a region-specific manner 
Use anatomically comprehensive databases of the developing  
human brain, including in situ hybridization, and microarray 
analyses** 
Include more research and evidence generated by 
complementary alternative medicine (CAM) 
Examine anti-NDD potential of nutrients, natural products and plant 
extracts, including those used in traditional Chinese medicine, 
Indian Ayurveda and Native/Latin-American or African folk 
medicine. 
 
*See, for example, 80, 81, 101-102  for details.  
** See 102-105 for details of NDD-associated susceptibility genes’ upregulation in the prefrontal cortex, 
and prenatal abundance of NDD-related (e.g., ASD-related) gene expression. 
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